Granisetron Kabi

Granisetron Kabi is a prescription medication that contains the active ingredient granisetron hydrochloride. It is supplied as an intravenous formulation, marketed in the European Union. Granisetron Kabi belongs to the 5‑HT3 receptor antagonist class and is used as an antiemetic to help prevent nausea and vomiting associated with chemotherapy or surgery. The product is administered by healthcare professionals under controlled conditions and is listed under ATC code A04AA10.

Granisetron Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings.

- Prevention of acute chemotherapy‑induced nausea and vomiting (CINV) following moderately or highly emetogenic regimens. - Prevention of delayed CINV when administered as part of a multimodal antiemetic protocol. - Prevention of postoperative nausea and vomiting (PONV) after general anesthesia. - Adjunct therapy in patients receiving radiation therapy who are at risk for emesis. - Use in pediatric oncology patients when dosing is determined by a qualified clinician.

The safety profile of Granisetron Kabi includes both common and less frequent serious adverse events.

Common: - Headache – mild to moderate intensity. - Constipation – may be transient. - Diarrhea – occasional and self‑limiting. - Dizziness – usually resolves without intervention. - Fatigue – generally mild.

Serious: - Cardiac arrhythmias, including QT interval prolongation, which may be clinically significant. - Severe hypersensitivity reactions such as anaphylaxis or angioedema. - Seizures – rare but reported in isolated cases.

When prescribing Granisetron Kabi, clinicians should consider several precautionary measures to ensure safe use.

- Assess baseline cardiac status, especially QT interval, as 5‑HT3 antagonists may affect cardiac repolarization. - Use cautiously in patients with a history of severe constipation or bowel obstruction. - Evaluate renal and hepatic function; dose adjustments may be required in significant impairment. - Avoid use in patients with known hypersensitivity to granisetron or any component of the formulation. - Consider potential risks when administered concomitantly with other QT‑prolonging agents. - Review pregnancy and lactation status, as safety data are limited.

Granisetron Kabi can interact with other medications, influencing its efficacy or safety profile.

Avoid: - Concurrent use with other QT‑prolonging drugs (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics). - Co‑administration with potent CYP3A4 inhibitors that may increase granisetron plasma levels. - Use with other serotonergic agents that could increase the risk of serotonin syndrome.

Use with caution: - Combination with other antiemetics (e.g., dexamethasone, aprepitant) may require dose adjustments. - Concurrent administration with drugs that affect electrolyte balance, such as diuretics, may influence cardiac risk. - Use with anesthetic agents that have emetogenic potential, monitoring for additive effects.